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Aim: Statins can induce pharmacologic preconditioning and thereby reduce infarct size. Cellular 
phosphatidylserine (PS) exposition occurs in the course of ischaemia and reperfusion and has been 
associated with injury. In this experiment we studied the effect of atorvastatin on PS exposition after 
a standardised ischaemia and reperfusion challenge.
Methods: In a double-blind randomised cross-over trial 30 healthy volunteers were allocated to 3 day 
treatment with atorvastatin (80 mg/day) and placebo (n=24), or placebo treatment twice (n=6). At 
the end of each treatment period, volunteers underwent 10 minutes of forearm ischaemic exercise. At 
reperfusion radiolabeled annexin A5 was administered intravenously and Gamma camera imaging of 
both hands was performed 1 and 4 hours after reperfusion.
Results: Annexin A5 targeting was not different between atorvastatin treatment (26.1±9.8% and 
24.0±9.5% respectively at 1 and 4 hours after reperfusion) and placebo treatment (25.6±11.0% and 
24.5±10.7%) (p=0.99). Our time control experiment did not reveal a carry-over effect.
Conclusions: Our results show that treatment with atorvastatin 80 mg does not reduce forearm PS 
exposition after ischaemic exercise. This suggests that the role of PS exposure in the prevention of 
ischemia and reperfusion injury by short term treatment with atorvastatin is limited.
J Atheroscler Thromb, 2012; 19:285-291.
Key words; Atorvastatin, Ischaemia-reperfusion injury, Phosphatidylserines, Annexin A5 scintigraphy, 
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Introduction
The cholesterol lowering action of statins 
(HMG-coenzyme A reductase inhibitors) and its asso-
ciated reduction in cardiovascular events have been 
well documented in numerous clinical trials1-4). Tradi-
tionally, this beneficial effect of statins has been 
explained by lowering of plasma cholesterol and sub-
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sequent reduced progression of atherosclerosis. Apart 
from its cholesterol lowering properties, statins have 
other (“pleiotropic”) actions, such as up-regulation of 
ecto-5’-nucleotidase5-7), activation of the phosphati-
dylinositol 3-kinase-Akt pathway8) and up-regulation 
of NO synthase9, 10) which all may increase tolerance 
against ischaemia and reperfusion (IR)11-13). Several 
animal studies have shown reduction of IR-injury as a 
result of statin treatment in both the heart and the 
kidney14-17). This putative protection may explain the 
clinical observation that early initiation of statin treat-
ment in patients with an acute cardiovascular event 
improves long-term prognosis as compared with a 
delayed start of this treatment18-20). Furthermore in 
two randomised clinical trials one day treatment with 
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Methods
After approval of the protocol (NCT00441597) 
by the Institutional Review Board of the Radboud 
University Nijmegen Medical Centre and in accor-
dance with the declaration of Helsinki (2008), 30 
healthy male volunteers (age 18-54) signed informed 
consent. All participants underwent medical screening 
to exclude cardiovascular disease, hypercholesterol-
emia, hypertension, diabetes mellitus, and impaired 
renal function. Furthermore serum values of creatinin 
kinase (CK) and alanine aminotransferase (ALT) were 
measured to exclude participants possibly at risk for 
adverse events due to atorvastatin use (rhabdomyolysis 
and toxic hepatitis).
In this double blind randomised cross-over trial 
(Fig.1) participants were allocated to treatment with 
either atorvastatin and placebo (n=24), or placebo 
treatment twice (n=6). The latter group served as a 
time-control. Furthermore, it allowed us to verify our 
assumptions on within subject variability and test-to-
test correlation of our annexin A5 scans. Placebo or 
atorvastatin (80 mg) was administered for three days, 
and at least 4 weeks were allowed between the two 
treatment periods as a wash-out. Atorvastatin 80mg 
(Pfizer, Capelle a/d IJssel, The Netherlands) was cap-
sulated to match placebo by the department of Clini-
cal Pharmacy (Radboud University Nijmegen Medical 
Centre, Nijmegen, The Netherlands according to 
GMP standards). In both treatment periods the first 
tablet was administered under supervision of the 
investigator, after venous blood sampling to determine 
fasting lipid profile. The participant was instructed to 
take the second capsule in the morning and to abstain 
from caffeine during the last 24 hours prior to isch-
aemic exercise. On day 3 after an overnight fast the 
last tablet was administered under supervision, again 
after assessment of fasting lipid profile and serum caf-
feine level to verify protocol compliance.
Sixty minutes after administration of the study 
medication in all participants maximal voluntary con-
traction force of the non-dominant forearm was mea-
sured with an isometric handgrip dynamometer. Sub-
sequently, the circulation of the non-dominant fore-
arm was occluded for 10 minutes with an upper arm 
cuff inflated to 200 mmHg. Directly after occlusion 
volunteers were asked to perform isometric contrac-
tions of the finger flexors at 50% of their maximum 
contraction force. These contractions were performed 
rhythmically with 5 seconds of contraction followed 
by 5 seconds of relaxation until exhaustion. The total 
duration of ischaemia was 10 minutes, independent of 
the duration of contractions.
atorvastatin prior to percutaneous coronary interven-
tion reduced myocardial injury and improved clinical 
outcomes in patients with acute coronary syn-
dromes21, 22).
Ischaemia induced phosphatidylserine (PS) expo-
sure on cardiomyocytes has been associated with 
reversible cellular damage and apoptosis23, 24). Treat-
ment to shield exposed PS with diannexin, a homodi-
mer of human annexin A5 (with high affinity for 
exposed phosphatidylserines) significantly reduces IR-
injury in the liver and kidney25, 26). Likewise, dian-
nexin prevents no-reflow in a rabbit cardiac ischemia-
reperfusion model27). These observations suggest a 
critical role for exposed PS in the development of IR-
injury. We have developed an experimental model to 
study PS exposure after IR in healthy volunteers. Our 
model uses radiolabeled recombinant annexin A5 to 
visualise PS-exposition that occurs after 10 minutes of 
forearm ischemia combined with isometric exercise28). 
Interventions that have been shown in preclinical and 
clinical research to modulate myocardial infarct size 
(ischaemic preconditioning, and administration of 
adenosine, dipyridamole, and caffeine) similarly mod-
ulate annexin A5 targeting in our forearm model, fur-
ther supporting a role for PS-exposure in IR-
injury28-30).
Using annexin A5 scintigraphy after voluntary 
ischaemic exercise in healthy males, we have recently 
shown that annexin A5 targeting after a short pretreat-
ment with rosuvastatin 20 mg once daily was signifi-
cantly reduced (16±1% and 18±2% respectively at 1 
and 4 hours after reperfusion) compared to placebo 
treatment (21±3% and 25±3%) (p＜0.05)31). As pre-
viously reported for other statins in preclinical research 
with infarct size as endpoint, this effect of rosuvastatin 
was inhibited by caffeine, an adenosine receptor 
antagonist31).
There is ample evidence from animal and clinical 
research that treatment for three days with high dose 
atorvastatin protects against IR-injury15, 21, 32-34). How-
ever, we do not know whether PS exposure relates to 
this clinical benefit of atorvastatin, as differences have 
been observed in the efficacy of various statins to 
inhibit HMG-CoA-reductase35) and to induce pleio-
tropic effects36).
Aim
We aim to assess the role of PS-modulation in 
the beneficial effect of atorvastatin on IR-injury. We 
tested the hypothesis that a short pretreatment with 
atorvastatin 80 mg reduces annexin A5 targeting in 
our forearm IR-model.
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Statistical Analysis
Values are expressed as mean±standard error 
(SE) unless indicated otherwise.
This study is the first to use our forearm IR-
model in a paired set-up in healthy volunteers. Based 
on previous studies, a between subject SD of 10% was 
predicted28-30). Conservatively assuming a correlation 
coefficient of 0.5 between first and second paired 
observation, we calculated that with an alpha of 0.05 
and a power of 90%, using 24 subjects allows us to 
find a difference in annexin A5 targeting of 7%. This 
is well in the range of our previous observation after 
treatment with rosuvastatin31). Furthermore 6 addi-
tional participants were randomised (in a double-blind 
fashion) to receive placebo treatment twice to serve as 
time control experiment. This time-control allows us 
to verify our assumptions regarding this power analy-
sis afterwards.
The effect of atorvastatin treatment on annexin 
A5 targeting and lipid profile was tested using ANOVA 
for repeated measurements. All statistical analyses were 
performed using SPSS 16.0 for Windows.
Results
Baseline characteristics of all participants are pre-
sented in Table 1. Caffeine levels were all under 0.85 
Immediately upon reperfusion 100 microgram 
recombinant human annexin A5, radiolabeled with 
450 MBq Technetium-99m was administered intrave-
nously into the dominant arm. One and four hours 
after this administration both hands were scanned 
simultaneously by use of a gamma camera (Orbiter 
camera equipped with low-energy high-resolution col-
limators; Siemens, Hoffman Estates, Ill, USA) as pre-
viously described28).
Caffeine plasma concentrations were determined 
using reversed-phase HPLC with UV detection set at 
273 nm37). Serum lipid profile (total-, HDL- and 
LDL-cholesterol and triglycerides), creatinine kinase 
(CK) and alaninine amino transferase (ALAT) were 
determined with a commercially available kit (Aeroset, 
Abbott, Santa Clara, Cal., USA).
Data Analysis
All the digitised gamma camera images were ana-
lysed offline by the same investigator (W.J.O.) using 
Hermes software (Nuclear Diagnostics, Stockholm, 
Sweden). A predefined region of interest was placed 
over the thenar muscle of both hands. Annexin A5 
targeting was expressed as the percentage difference in 
counts/pixel between the experimental (non-domi-
nant) hand and the control hand as previously 
described28).
Fig.1. Study protocol. From the 30 participants 12 were randomised to 3 days of atorvastatin treatment fol-
lowed by three days of placebo treatment. 12 Participants were randomised to first 3 days of placebo 
treatment and next 3 days atorvastatin treatment, and 6 participants were randomised to placebo treat-
ment twice. At day three of treatment participants performed 10 minutes of ischemic forearm exercise. 
Upon reperfusion Tc-99m labelled annexin A5 was administered and scintigraphy was performed 1 
and 4 hours after reperfusion.  Between both treatment periods a 4 week interval was observed.
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effect of atorvastatin on annexin A5 targeting after 
voluntary ischaemic exercise. This indicates that in 
our forearm model treatment with atorvastatin, in a 
dose and duration as previously used in clinical trials 
with patients who present with coronary syn-
dromes21, 22, 32), does not modulate PS exposition after 
IR, in contrast to treatment with rosuvastatin, as 
reported recently31). As the protective action of atorv-
astatin in a setting of ischemia and reperfusion has 
been convincingly shown in multiple animal experi-
ments33, 34) and even in several clinical trials21, 22, 38), we 
conclude that PS modulation is not likely involved in 
the protective mechanism of atorvastatin.
During reperfusion after an ischaemic event, 
multiple detrimental processes take place simultane-
ously including formation of radical oxygen species 
(ROS), cellular and mitochondrial calcium overload, 
and a rapid increase (restoration) in pH39). These 
actions result in mitochondrial damage caused by 
opening of the mitochondrial permeability transition 
pore (MPTP), activation of caspases and subsequent 
cell damage and possible cell death (by either necrosis 
or apoptosis)40).
PS exposition is recognised to be part of the sig-
nalling cascade in the course of apoptosis41). It attracts 
phagocytes which remove the dying cell before its 
remnants evoke an inflammatory response42). The 
importance of PS exposition in developing tissue dam-
age after IR injury was clearly demonstrated in several 
experiments where IR-injury could be reduced by 
mg/L, indicating satisfactory compliance to the 24 
hours caffeine abstinence. The annexin A5 targeting 
was not different between atorvastatin treatment 
(26.1±2.0% and 24.0±1.9% respectively at 1 and 4 
hours after reperfusion) and placebo treatment (25.6±
2.4% and 24.5±2.2%) (p=0.999) (Fig.2).
Three day treatment with atorvastatin signifi-
cantly reduced total cholesterol (from 4.15±0.10 
mmol/L to 3.44±0.10 mmol/L) and LDL cholesterol 
(from 2.31±0.10 mmol/L to 1.84±0.10 mmol/L as 
compared to placebo treatment; p＜0.001 for both 
comparisons). HDL cholesterol and triglyceride levels 
were unaffected by atorvastatin (from 1.22±0.04 to 
1.25±0.05 for HDL-C, and from 0.93±0.08 to 
0.80±0.09 for triglycerides).
Workload (50% of the maximal strength ＊ dura-
tion of ischaemic exercise) did not significantly differ 
between both study days (4260±284 kg＊sec and 
4253±219 kg＊sec after atorvastatin and placebo 
respectively (p=0.96), indicating that potential differ-
ences in ischaemic challenge did not confound the 
observed lack of effect on annexin A5 targeting.
In the time control group (n=6) the annexin A5 
targeting after the first visit was 23.5±5.5% and 
23.2±6.5% (respectively at 1 and 4 hours after reper-
fusion) and 30.2±6.1% and 20.3±7.8% after the 
second visit (Fig.3). The between-subject standard 
deviations in annexin A5 targeting were 13.5%, 
15.8%, 15.0% and 9.3% at 1 and 4 hours for visit 1 
and 2 respectively. Within subject correlation was 0.93 
and 0.79 at 1 and 4 hours respectively. This reproduc-
ibility should have allowed us to detect a difference in 
targeting between placebo and atorvastatin of at least 
7%, closely resembling our initial power calculation.
Discussion
The novel finding of this study is the lack of 
Table 1. Baseline characteristics of all participants (n=30)
Mean±S.D.
Age (years)
BMI (kg/m2)
Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)
Heart rate (bpm)
Glucose (mmol/L)
Total cholesterol (mmol/L)
Triglycerides (mmol/L)
HDL-C (mmol/L)
LDL-C(mmol/L)
23.3±6.6
22.4±2.4
126±8
71±10
62±8
4.6±0.7
4.0±0.6
1.19±0.94
1.33±0.26
2.19±0.65
Fig.2. Annexine A5 targeting 1 and 4 hours after reperfu-
sion, after placebo (open bars) and atorvastatin (closed 
bars) treatment. Bars represent mean±SE.
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ment duration could account for the difference in 
annexin A5 targeting in these experiments. We have 
previously shown in humans that activation of ecto-
5’-nucleotidase mediates prevention of PS exposure by 
rosuvastatin after IR. The effect of statins on ecto-5’-
nucleotidase appears to occur rapidly6, 7). For example 
Sanada et al. found a significant increase of ecto-5’-
nucleotidase activity in dogs for different statins 
(pravastatin, pitavastatin and cerivastatin) already 10 
minutes after treatment7). Thus, our discrepant results 
between rosuvastatin and atorvastatin are not likely 
explained by differences in treatment duration but 
rather reflect a difference in pharmacodynamics 
between these two statins. There are significant differ-
ences between several statins in their efficacy to lower 
LDL cholesterol48). Moreover, pleiotropic effects have 
been shown to differ between lipophilic statins (e.g. 
atorvastatin) and hydrophilic statins (e.g. rosuvas-
tatin). Lipophilic statins have been reported to render 
endothelial and vascular smooth muscle cells more 
susceptible to apoptosis than hydrophilic statins49). In 
humans rosuvastatin inhibits Rho/Rho kinase activity 
to a greater extent than atorvastatin at a dose that 
equally reduced LDL cholesterol36). Moreover hydro-
philic statins have been suggested to be superior in 
reducing event rate after a primary acute coronary 
syndrome in normocholesterolemic patients50).
Conclusion
Our results show that treatment with atorvastatin 
80 mg does not reduce forearm PS exposition after 
ischaemic exercise. This suggests that the role of PS 
exposure in the prevention of ischemia and reperfu-
sion injury by short term treatment with atorvastatin 
is limited.
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